1. Everi Holdings (EVRI)

EVRI: Analysts Upgrade Price Target to $12.07

Summary: Everi Holdings (EVRI) is a leading supplier of entertainment and technology solutions for the casino and digital gaming industry. Everi has seen fluctuations in its portfolio allocation over the last quarter, with some firms increasing and others decreasing their holdings. The average one-year price target for EVRI has been revised to $12.07 per share, representing a potential increase of 33.52% from the latest closing price.

🗓️ Alert Date: July 25th

🟢 Alert Sentiment: Bullish

🚨 7D Alert Price Change: +42% ▲

2. Lamb Weston (LW)

LW Stock Plummets: Product Woes Cause $330M Sales Guidance Cut

Summary: Lamb Weston faced significant problems with its transition to a new software system, resulting in a decline in stock price by over 20% and a reduction in sales guidance by $330 million. The transition negatively impacted sales, net income, and earnings before interest, taxes, depreciation, and amortization. Investors should be aware of the challenges Lamb Weston faced with the ERP system rollout and its impact on financial performance.

🗓️ Alert Date: July 26th

🔴 Alert Sentiment: Bearish

🚨 7D Alert Price Change: -23% ▼

3. CBRE Group (CBRE)

CBRE Surges 9% on Strong Q2 Results and Strategic Acquisitions

Summary: CBRE's shares were up more than 10% this week, reflecting positive sentiments. The company reported a year-over-year revenue increase in its Advisory Services segment and exceeded the Zacks Consensus Estimate for core earnings per share. CBRE also announced plans to combine its project management business with its Turner & Townsend subsidiary, showing potential for growth and expansion.

🗓️ Alert Date: July 25th

🟢 Alert Sentiment: Bullish

🚨 7D Alert Price Change: +13% ▲

4. Biogen (BIIB)

BIIB Faces Setback with SAGE-324 Trial Results

Summary: Biogen, a leading biotechnology company, experienced a setback alongside partner Sage Therapeutics with disappointing results from a late-stage clinical trial for SAGE-324 (BIIB124) for essential tremor. This news led to a significant pre-market stock price decline for both companies. Biogen does not plan to continue the development of SAGE-324 for essential tremor following these results.

🗓️ Alert Date: June 24th

🔴 Alert Sentiment: Bearish

🚨 7D Alert Price Change: -5% ▼

5. Hasbro (HAS)

HAS: Hasbro’s Strategic Focus and Earnings Potential Trending Up

Summary: Hasbro (HAS) is recommended for investors due to improved earnings estimates and a favorable valuation. Despite facing challenges in core segments, Hasbro has outperformed industry players and is focusing on cost-competitive supply chain improvements. The company's strategic focus on innovative product lines and successful licensing agreements make it an appealing investment opportunity.

🗓️ Alert Date: June 24th

🟢 Alert Sentiment: Bullish

🚨 7D Alert Price Change: +9% ▲